May 5, 2011 -- AstraZeneca has been partnering with China companies since it first established a China presence in 1993. The company makes use of local innovative scientific talent to help drive its own R&D efforts, allowing the company to achieve more than it can alone. In an interview, Steve Yang, PhD, Vice-President of AstraZeneca and Head of R&D for Asia, discusses the company’s strategy for China research in light of the country’s pharma exploding market growth. More details...
Stock Symbol: (NYSE: AZN)/p>
